Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

Overview of attention for article published in Journal of Hematology & Oncology, September 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#42 of 1,307)
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 5 news outlets
blogs: 1 blog

twitter: 3 X users
patent: 12 patents

Citations

dimensions_citation: 142 Dimensions

Readers on

mendeley: 206 Mendeley

Summary News Blogs X Patents Dimensions citations

So far, Altmetric has seen 12 patents that reference this research output.

Methods of using bispecific CD33 and CD3 binding proteins

Grant US-11753469-B2

United States of America

Binding molecules with modified J-chain

Grant US-11639389-B2

United States of America

Modified J-chain

Grant US-11555075-B2

United States of America

LONG ACTING BI-SPECIFIC T CELL ENGAGERS TARGETING CD3 AND CD47

Application WO-2022105787-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 8 additional patents.